Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer

Disease Markers

Volumn 19, Issue 6, 2003, Pages 267-272

  Ayude, Daniel ^a   De La Cadena, María Páez ^a   Cordero, Oscar Javier ^b   Nogueira, Montserrat ^b   Ayude, José ^a   Fernández Briera, Almudena ^a   Rodríguez Berrocal, Francisco Javier ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Alpha L fucosidase; CD26; Colorectal cancer; Diagnosis; Serum

Indexed keywords

ALPHA LEVO FUCOSIDASE; DIPEPTIDYL PEPTIDASE IV; TUMOR MARKER;

ARTICLE; CALCULATION; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SERUM;

EID: 3042714482     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/834309     Document Type: Article

References (27)

1. http://www.iarc.fr, International Agency for Research on Cancer. Cancer incidence and mortality data bases, last accessed 1 July, 2003.
2. S. Srivastava, The Early Detection Research Network Second Annual Scientific Workshop 14-16 October 2001, Seatle, Washington, USA, Dis. Markers 18 (2002), 1.
3. American Society of Clinical Oncology, Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer, J. Clin. Oncol. 14 (1996), 2843-2877.
4. C.E. Desch, A.B. 3rd Benson, T.J. Smith, P.J. Flynn, C. Krause, C.L. Loprinzi, B.D. Minsky, N.J. Petrelli, D.G. Pfister and M.R. Somerfield, Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology, J. Clin. Oncol. 17 (1999), 1312-1321.
5. A.B. 3rd Benson, C.E. Desch, P.J. Flynn, C. Krause, C.L. Loprinzi, B.D. Minsky, N.J. Petrelli, D.G. Pfister, T.J. Smith and M.R. Somerfield, 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines, J. Clin. Oncol. 18 (2000), 3586-3588.
6. R.C. Jr Bast, P. Ravdin, D.F. Hayes, S. Bates, H. Jr Fritsche, J.M. Jessup, N. Kemeny, G.Y. Locker, R.G. Mennel and M.R. Somerfield, 2000 update recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology, J. Clin. Oncol. 19 (2001), 1865-1878.
7. J.W.W. Coebergh, Challenges and pitfalls of mass-screening in the European Union, Eur. J. Cancer 36 (2000), 1469-1472.
8. Advisory Committee on Cancer Prevention, Recommendations on cancer screening in the European Union, Eur. J. Cancer 36 (2000), 1473-1478.
9. S.W. Vernon, Participation in colorectal cancer screening: a review, J. Natl. Cancer Inst. 89 (1997), 1406-1422.
10. D.F. Rasnsohoff and R.S. Sandler, Screening for colorectal cancer, N. Engl. J. Med. 346 (2002), 40-44.
11. O.J. Cordero, D. Ayude, M. Nogueira, F.J. Rodríguez-Berrocal and M. Páez de la Cadena, Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer, Br. J. Cancer 83 (2000), 1139-1146.
12. D. Ayude, J. Fernández-Rodríguez, F.J. Rodríguez- Berrocal, V.S. Martínez-Zorzano, A. de Carlos, E. Gil and M. Páez de la Cadena, Value of the serum α-L-fucosidase activity in the diagnosis of colorectal cancer, Oncology 59 (2000), 310-316.
13. J. Ten Kate, J.T. Wijnen, J. Boldwijn, P.M. Khan and F.T. Bosman, Immunohistochemical localization of adenosine deaminase complexingn protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity, Histochem. J. 17 (1985), 23-31.
14. M. Páez de la Cadena, J. Fernández, A. de Carlos, V.S. Martínez-Zorzano, E. Gil-Martín and F.J. Rodríguez- Berrocal, Low levels of α-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes' stage, Int. J. Oncol. 9 (1996), 747-754.
15. J. Ten Kate, H.F. van den Ingh, P.M. Khan and F.T. Bosman, Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma, Int. J. Cancer 37 (1986), 479-485.
16. A. Merino-Trigo, F.J. Rodríguez-Berrocal, E. de Miguel and M. Páez de la Cadena, Activity and properties of alpha-L-fucosidase are dependent on the state of enterocytic differentiation of HT-29 colon cancer cells, Int. J. Biochem. Cell Biol. 34 (2002), 1291-1303.
17. P. Hermanek and L.H. Sobin, UICC TNM Clasification of the malignant tumours: Colon and Rectum, 4th edition, 2nd revision, Springer, London, 1992, pp. 52-56.
18. R.J. O'Hara, J. Greenman, P.J. Drew, A.W. McDonald, G.S. Duthie, P.W. Lee and J.R. Monson, Impaired interleukin-12 production is associated with a defective anti-tumour response in colorectal cancer, Dis. Colon Rectum 40 (1998), 460-463.
19. O.J. Cordero, F.J. Salgado, J.E. Viñuela and M. Nogueira, Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes, Immunobiology 197 (1997), 522-533.
20. J. Fernández Rodríguez, M. Páez de la Cadena, V.S. Martínez-Zorzano and F.J. Rodríguez-Berrocal, Fucose levels in sera and in tumours of colorectal adenocarcinoma patients, Cancer Lett 121 (1997), 147-153.
21. J.S. Mandel, J.H. Bond, T.R. Church, D.C. Snover, G.M. Bradley, L.M. Schuman and F. Ederer, Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N. Engl. J. Med. 328 (1993), 1365-1371.
22. O. Kronborg, C. Fenger, J. Olsen, O.D. Jorgensen and O. Sondergaard, Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet 348 (1996), 1467-1471.
23. J.D. Hardcastle, J.O. Chamberlain, M.H. Robinson, S.M. Moss, S.S. Amar, T.W. Balfour, P.D. James and C.M. Mangham, Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet 348 (1996), 1472-1477.
24. Y. Niv, M. Lev-El, G. Fraser, G. Abuksis and A. Tamir, Protective effect of faecal occult blood test screening for colorectal cancer worse prognosis for screening refusers, Gut 50 (2002), 33-37.
25. D.F. Ransohoff and C.A. Lang, Screening for colorectal cancer with the fecal occult blood test: a background paper, Ann Intern Med 126 (1997), 811-822.
26. G. Traverso, A. Shuber, B. Levin, C. Johnson, L. Olsson, D.J. Jr Schoetz, S.R. Hamilton, K. Boynton, K.W. Kinzler and B. Vogelstein, Detection of APC mutations in fecal DNA from patients with coloretal tumors, N. Engl. J. Med. 346 (2002), 311-320.
27. Y. Ito, S. Kobayashi, T. Taniguchi, O. Kainuma, T. Hara and T. Ochiai, Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: Comparison with tissue samples, Int. J. Oncol. 20 (2002), 1263-1268.